Augmedix (NASDAQ:AUGX) Downgraded to Hold at Maxim Group

Augmedix (NASDAQ:AUGXGet Free Report) was downgraded by equities research analysts at Maxim Group from a “buy” rating to a “hold” rating in a report issued on Tuesday, Briefing.com reports. They currently have a $5.00 price objective on the stock. Maxim Group’s price objective points to a potential upside of 113.68% from the stock’s current price.

Several other research analysts have also commented on AUGX. B. Riley initiated coverage on shares of Augmedix in a report on Wednesday, April 3rd. They issued a “buy” rating and a $5.50 price target for the company. Evercore ISI lowered shares of Augmedix from an “outperform” rating to an “inline” rating and reduced their target price for the company from $5.00 to $1.50 in a research note on Tuesday.

Get Our Latest Research Report on Augmedix

Augmedix Price Performance

AUGX opened at $2.34 on Tuesday. Augmedix has a 1-year low of $2.22 and a 1-year high of $6.25. The company has a 50-day moving average of $3.47 and a 200-day moving average of $4.49. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.41 and a current ratio of 2.41. The company has a market capitalization of $114.59 million, a P/E ratio of -5.20 and a beta of 0.03.

Augmedix (NASDAQ:AUGXGet Free Report) last posted its quarterly earnings results on Monday, March 18th. The company reported ($0.09) EPS for the quarter. Augmedix had a negative net margin of 42.74% and a negative return on equity of 308.50%. The business had revenue of $12.68 million during the quarter, compared to analyst estimates of $12.30 million. Equities analysts expect that Augmedix will post -0.51 EPS for the current fiscal year.

Insider Buying and Selling at Augmedix

In other Augmedix news, insider Ian Shakil sold 45,906 shares of the business’s stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $4.11, for a total transaction of $188,673.66. Following the completion of the transaction, the insider now directly owns 95,665 shares of the company’s stock, valued at approximately $393,183.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 251,323 shares of company stock valued at $1,005,527 in the last ninety days. Company insiders own 10.97% of the company’s stock.

Institutional Trading of Augmedix

Institutional investors have recently made changes to their positions in the stock. Acadian Asset Management LLC acquired a new stake in shares of Augmedix in the 3rd quarter worth approximately $48,000. Oppenheimer Asset Management Inc. acquired a new stake in shares of Augmedix in the 1st quarter worth approximately $56,000. SG Americas Securities LLC acquired a new stake in shares of Augmedix in the 1st quarter worth approximately $57,000. Symmetry Peak Management LLC acquired a new stake in shares of Augmedix in the 4th quarter worth approximately $88,000. Finally, Worth Venture Partners LLC acquired a new stake in shares of Augmedix in the 3rd quarter worth approximately $83,000. 87.11% of the stock is owned by institutional investors and hedge funds.

About Augmedix

(Get Free Report)

Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.

Featured Stories

Receive News & Ratings for Augmedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Augmedix and related companies with MarketBeat.com's FREE daily email newsletter.